In terms of potential mechanisms for this varied response, it is possible that some TP53WT CLL samples may be less sensitive to MDM2 inhibitors due to impaired function of downstream targets of p53. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.